Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study

[1]  C. Rudin,et al.  Small-cell lung cancer , 2021, Nature Reviews Disease Primers.

[2]  M. Hallek,et al.  Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma , 2020, Leukemia & lymphoma.

[3]  J. Burke,et al.  First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  F. Bosch,et al.  Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study , 2018, Leukemia.

[5]  W. Hiddemann,et al.  Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study , 2018, Haematologica.

[6]  W. Klapper,et al.  Obinutuzumab for the First‐Line Treatment of Follicular Lymphoma , 2017, The New England journal of medicine.

[7]  M. Hallek,et al.  Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review , 2017, Therapeutic advances in hematology.

[8]  J. Gribben,et al.  Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. , 2016, The Lancet. Oncology.

[9]  E. Kimby,et al.  Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update , 2015, Leukemia & lymphoma.

[10]  E. Hellriegel,et al.  Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites , 2015, Cancer Chemotherapy and Pharmacology.

[11]  J. Burke,et al.  Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. , 2014, Blood.

[12]  L. Gil,et al.  Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma , 2014, Medical Oncology.

[13]  D. Carbone,et al.  Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  J. Epstein,et al.  Small cell carcinoma of the prostate , 2014, Nature Reviews Urology.

[15]  M. Stauch,et al.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial , 2013, The Lancet.

[16]  N. Tageja.  Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma , 2011, Clinical Medicine Insights. Oncology.

[17]  Bruce D Cheson,et al.  Bendamustine: rebirth of an old drug. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Jacques Corbeil,et al.  Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents , 2008, Clinical Cancer Research.

[19]  D. Wallwiener,et al.  Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  A. Schneeweiss,et al.  Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study , 2007, Anti-cancer drugs.

[21]  N. Niederle,et al.  Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  R. Souchon,et al.  Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC , 2005, Anti-cancer drugs.

[23]  Charles R. Thomas,et al.  Thymic carcinoma: state of the art review. , 2004, International journal of radiation oncology, biology, physics.

[24]  D. Strumberg,et al.  Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines , 1996, Anti-cancer drugs.

[25]  R. Preiss,et al.  [The pharmacokinetics of bendamustine (Cytostasane) in humans]. , 1985, Die Pharmazie.

[26]  M. Hartmann,et al.  Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393 and 3943. , 1972, Biochimica et biophysica acta.

[27]  W. Ozegowski,et al.  Aminosäureantagonisten. III. ω-[Bis-(β-chloräthyl)-amino-benzimidazolyl-(2)]-propion- bzw. -buttersäuren als potentielle Cytostatika , 1963 .

[28]  P. Iyengar,et al.  Small Cell Lung Cancer, Version 2.2022 , 2021 .

[29]  E. Thiel,et al.  Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. , 2007, Lung cancer.

[30]  Chad A. LaGrange,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .